Educating Through Medical Animations, Cases and More | Free CME Activities

Interactive Cases

Search

Filter Content

Page 7 of 7

Results 451 - 509 of 509

How to Recognize and Diagnose IPF

What Is IPF?

What’s Next for IPF Therapy?

Applying the Evidence on Antifibrotic Agents for IPF

What Do the Experts Say about New Developments in the Diagnosis of ILD?

Is the delivery system a good match for your patients with COPD?

Stepping up or stepping down – which direction for COPD patients?

What’s the 2017 GOLD standard for managing patients with COPD?

UIP, IPF, NSIP, CHP: Making Sense of the Letters

t2diabetes-louise

Getting to Goal Can Be Difficult: Louise

t2diabetes-brian

Getting to Goal Can Be Difficult: Brian

Considering Biosimilars in Patients Failing their Initial Biologic

When to Switch? Biologically Experienced Patients with Spondyloarthritis

Innovator or Biosimilar for a Patient with Rheumatoid Arthritis

IL-gastro-case3

Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?

IL-gastro-case2

Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic

IL-gastro-case1

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Switching Between Biologics: Is a Biosimilar an Option?

When to Switch? Biologically Experienced Psoriasis Patients

Innovator or Biosimilar for a Patient with Psoriasis

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer

Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases

Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Are You Ready to Use Biosimilars in Your Practice?

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Radiologic Features of IPF

Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs

Elizabeth: Loves the outdoors but bothered by persistent cough and GERD

Toni: Too tired to continue teaching and experiencing painful heartburn

Individualizing Patient Education in Treatment Choice: Practical Strategies

A 30 y/o Female w/2-year History of Shoulder Weakness and Elevated AST and ALT

32 y/o Male w/Progressive Weakness, Dilated Cardiomyopathy & Respiratory...

A 60 y/o Male w/4-year History Of Shoulder Weakness

Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Individualizing Patient Education in Treatment Choice: Practical Strategies

Addressing Common Barriers to Adherence

Approach to Genetic Testing in Myopathies

Molecular Diagnosis of Limb-Girdle Muscle Weakness

Discovering New Drugs for IPF

Biomarkers for IPF

New Trends in IPF

New Trends in IPF

Treatment Dilemmas Case Study: Harrison

A New Era in IPF: Trials and Treatments

Highlights from ATS 2014: Discussions on Clinical Trial Data

Highlights from ATS 2014: Update on Predicting Clinical Progression

Highlights from ATS 2014: Top Line Clinical Trial Results - ASCEND, INPULSIS, and PANTHER

Exciting IPF Developments from 2015 ERS

Exciting Developments from 2015 CHEST

Page 7 of 7